← back to search

Alexander R. Moschen

Johannes Kepler University of Linz · AT
Area of research
Epidemiology · Genetics
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Inflammatory Bowel Disease, Gut microbiota and health, and Adipokines, Inflammation, and Metabolic Diseases.
h-index
61
citations
21,489
works
219
NIH funding
primary concept
Medicine
email

Recent publications

Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort study.
2026cited by 0position: contributordoi
Multi-modal atlas of lifestyle interventions reveals malleability of ageing-linked molecular features
2025cited by 3position: contributordoi
Longitudinal multi-omic evaluation of biomarkers of health and ageing over smoking cessation intervention
2025cited by 2position: contributordoi
Systemic multi-omic remodelling underlies health benefits of intermittent fasting
2025cited by 2position: contributordoi
Filgotinib bei Colitis ulcerosa: ein Review
Journal für Gastroenterologische und Hepatologische Erkrankungen 2024cited by 0position: contributordoi
A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma.
2023cited by 28position: contributordoi
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Intestinal Research 2023cited by 3position: contributordoi
Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics.
2022cited by 20position: contributordoi
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
2022cited by 0position: contributordoi
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade.
2021cited by 270position: contributordoi
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
2021cited by 69position: contributordoi
Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
2021cited by 65position: contributordoi
Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients.
2021cited by 50position: contributordoi
When the genome bluffs: a tandem duplication event during generation of a novel Agmo knockout mouse model fools routine genotyping.
2021cited by 14position: contributordoi
Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
2021cited by 10position: contributordoi
Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19.
2021cited by 9position: contributordoi
Immunologically relevant aspects of the new COVID-19 vaccines-an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper.
2021cited by 5position: contributordoi
Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe : Ein Positionspapier der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und des Ärzteverbands Deutscher Allergologen (AeDA).
2021cited by 1position: contributordoi
B and T Cell Response to SARS-CoV-2 Vaccination in Health Care Professionals With and Without Previous COVID-19
2021cited by 0position: contributordoi
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
2021cited by 0position: contributordoi
Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease.
2020cited by 237position: contributordoi
Prebiotic Effects of Partially Hydrolyzed Guar Gum on the Composition and Function of the Human Microbiota—Results from the PAGODA Trial
Nutrients 2020cited by 60position: contributordoi
Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease.
2020cited by 24position: contributordoi
Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.
2020cited by 19position: contributordoi
IBD in the time of corona - vigilance for immune-mediated diseases.
2020cited by 1position: contributordoi
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
2019cited by 355position: contributordoi
Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD.
2019cited by 48position: contributordoi
The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism
Cell Metabolism 2014cited by 116position: middledoi
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus
Nature Medicine 2013cited by 254position: middledoi
Heterogeneity of fibrosis patterns in non‐alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways
Liver International 2013cited by 53position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 15 papers (2020–2026)Timon E. Adolph · University Hospital Innsbruck7 papers (2020–2023) · 4 papers (2021–2023)Michael Knoflach · VASCage3 papers (2025–2025)Elisa Redl · Medical University of Vienna3 papers (2025–2025)Sophia J. Kiechl · Population Health Research Institute3 papers (2025–2025)Hermann Stuppner · Universität Innsbruck3 papers (2025–2025)Thomas R. Kreil · Takeda (Austria)3 papers (2021–2022)Tobias Greitemeyer · Universität Innsbruck3 papers (2025–2025)Chiara Herzog · University of Edinburgh3 papers (2025–2025)Herbert Tilg · University Hospital Innsbruck3 papers (2020–2023)Charlotte D. Vavourakis · University of Amsterdam3 papers (2025–2025)Wolfgang Schobersberger · UMIT - Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik3 papers (2025–2025)Birgit Weinberger · Hofstra University3 papers (2025–2025)Martin Widschwendter · Pomeranian Medical University3 papers (2025–2025)Philip Rosenstiel · Vall d'Hebron Hospital Universitari3 papers (2020–2023)Magdalena Hagen · Universität Innsbruck3 papers (2025–2025)Peter Widschwendter · Springer Nature3 papers (2025–2025)Christoph Grander · University Hospital Innsbruck3 papers (2020–2023)Sonja Sturm · University of Innsbruck3 papers (2025–2025)